OraSure Technologies Inc
OSUR2.400USD
-0.170-6.61%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
173.44MMarket Cap
LossP/E TTM
More Details of OraSure Technologies Inc Company
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
OraSure Technologies Inc Info
Ticker SymbolOSUR
Company nameOraSure Technologies Inc
IPO dateNov 17, 1986
CEOMs. Carrie Eglinton Manner
Number of employees501
Security typeOrdinary Share
Fiscal year-endNov 17
Address220 E First St
CityBETHLEHEM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code18015
Phone15036416115
Websitehttps://www.orasure.com/
Ticker SymbolOSUR
IPO dateNov 17, 1986
CEOMs. Carrie Eglinton Manner
Company Executives of OraSure Technologies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
158.15K
+72.80%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
153.32K
+4.16%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Steven Boyd ,
Mr. Steven Boyd ,
Independent Director
Independent Director
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
158.15K
+72.80%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
153.32K
+4.16%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Net product and services revenues - COVID-19
14.40M
46.09%
Net product and services revenues - HIV
9.86M
31.54%
Net product and service revenues -Molecular Products
4.13M
13.21%
Other revenues - Other non Product revenues
1.40M
4.47%
Net product and services revenues - Risk assessment testing
994.00K
3.18%
Other
474.00K
1.52%
By RegionUSD
Name
Revenue
Proportion
United States
19.85M
63.54%
Africa (Region)
8.03M
25.69%
Europe
2.12M
6.78%
Other Regions
1.25M
3.99%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Net product and services revenues - COVID-19
14.40M
46.09%
Net product and services revenues - HIV
9.86M
31.54%
Net product and service revenues -Molecular Products
4.13M
13.21%
Other revenues - Other non Product revenues
1.40M
4.47%
Net product and services revenues - Risk assessment testing
994.00K
3.18%
Other
474.00K
1.52%
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Private Management Group, Inc.
7.61%
BlackRock Institutional Trust Company, N.A.
7.58%
The Vanguard Group, Inc.
5.81%
Neuberger Berman, LLC
5.79%
Altai Capital Management, L.P.
5.23%
Other
67.98%
Shareholders
Shareholders
Proportion
Private Management Group, Inc.
7.61%
BlackRock Institutional Trust Company, N.A.
7.58%
The Vanguard Group, Inc.
5.81%
Neuberger Berman, LLC
5.79%
Altai Capital Management, L.P.
5.23%
Other
67.98%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.12%
Investment Advisor/Hedge Fund
27.45%
Hedge Fund
21.36%
Individual Investor
5.12%
Research Firm
2.35%
Pension Fund
0.44%
Bank and Trust
0.30%
Venture Capital
0.09%
Insurance Company
0.04%
Other
2.73%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
451
67.31M
92.04%
-15.49M
2025Q2
473
72.08M
98.55%
-16.70M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
2023Q3
456
72.50M
98.73%
-4.51M
2023Q2
452
70.73M
96.51%
-2.77M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Private Management Group, Inc.
5.46M
7.47%
+1.04M
+23.64%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.43M
7.43%
-141.00K
-2.53%
Jun 30, 2025
The Vanguard Group, Inc.
4.17M
5.7%
-120.08K
-2.80%
Jun 30, 2025
Neuberger Berman, LLC
4.16M
5.68%
-124.14K
-2.90%
Jun 30, 2025
Altai Capital Management, L.P.
3.75M
5.13%
+1.59M
+73.37%
Sep 02, 2025
Dimensional Fund Advisors, L.P.
3.84M
5.25%
+14.96K
+0.39%
Jun 30, 2025
Renaissance Technologies LLC
2.28M
3.11%
-294.84K
-11.47%
Jun 30, 2025
Systematic Financial Management, L.P.
2.23M
3.05%
+581.93K
+35.33%
Jun 30, 2025
Acadian Asset Management LLC
2.19M
3%
-563.24K
-20.44%
Jun 30, 2025
American Century Investment Management, Inc.
2.08M
2.85%
-423.60K
-16.91%
Jun 30, 2025
View more
Related ETFs
Updated: 22 hours ago
Updated: 22 hours ago
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.47%
iShares US Small Cap Value Factor ETF
0.38%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.07%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Avantis US Small Cap Equity ETF
0.03%
WisdomTree US SmallCap Fund
0.03%
iShares US Small-Cap Equity Factor ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.47%
iShares US Small Cap Value Factor ETF
Proportion0.38%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.07%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.03%
WisdomTree US SmallCap Fund
Proportion0.03%
iShares US Small-Cap Equity Factor ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
